Reduction of myocardial ischemia-reperfusion injury with pre- and postconditioning: Molecular mechanisms and therapeutic targets

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 1, 2008, Pages 47-65

  Galagudza, Michael M ^a,b   Blokhin, Ilia O ^a   Shmonin, Aleksey A ^a   Mischenko, Kirill A ^a  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

Author keywords

Cardioprotection; Heart; Infarct size; Ischemia reperfusion injury; Postconditioning; Preconditioning

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ARGININE; BIMAKALIM; BRADYKININ; CAPTOPRIL; CATECHOLAMINE DERIVATIVE; CROMAKALIM; DIAZOXIDE; G PROTEIN COUPLED RECEPTOR; INHALATION ANESTHETIC AGENT; ISOFLURANE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; OMAPATRILAT; OPIATE PEPTIDE; PENTOBARBITAL; PHOSPHODIESTERASE V INHIBITOR; PINACIDIL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL; TIOPRONIN; UNINDEXED DRUG; VARDENAFIL; CYCLIC GMP DEPENDENT PROTEIN KINASE;

CLINICAL PROTOCOL; CONDITIONING; DRUG MECHANISM; EXERCISE; EXERCISE TOLERANCE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTHERMIA; ISCHEMIC PRECONDITIONING; MECHANICAL STIMULATION; MEDIATOR; MUSCLE STRETCHING; NONHUMAN; POSTCONDITIONING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TEMPERATURE; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; REACTIVE OXYGEN SPECIES;

EID: 43649095490     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908783884966     Document Type: Review

References (194)

1. Levi, F.; Lucchini, F.; Negri, E.; La Vecchia, C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart, 2002, 88, 119-124.
2. Piper, H.M.; Garcia-Dorado, D.; Ovize, M. A fresh look at reperfusion injury. Cardiovasc. Res., 1998, 38, 291-300.
3. Murry, C.E.; Jennings, R.B.; Reimer, K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-1136.
4. Downey, J.M.; Cohen, M.V. Reducing infarct size in the setting of acute myocardial infarction. Prog. Cardiovasc. Dis., 2006, 48, 363-371.
5. Kloner, R.A.; Bolli, R.; Marban, E.; Reinlib, L.; Braunwald, E. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLB1 workshop. Circulation, 1998, 97, 1848-1867.
6. Evrengul, H.; Seleci, D.; Tanrverdi, H.; Kaftan, A. The antiarrhythmic effect and clinical consequences of ischemic preconditioning. Coron. Artery. Dis., 2006, 17, 283-288.
7. Hagar, J.M.; Hale, S.L.; Kloner, R.A. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ. Res., 1991, 68, 61-68.
8. Laude, K.; Beauchamp, P.; Thuillez, C.; Richard, V. Endothelial protective effects of preconditioning. Cardiovasc. Res., 2002, 55, 466-473.
9. Moolman, J.A.; Hartley, S.; Van Wyk, J.; Marais, E.; Lochner, A. Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovasc. Drugs. Ther., 2006, 20, 13-25.
10. Lamers, J.M. Preconditioning and limitation of stunning: one step closer to the protected protein(s)? Cardiovasc. Res., 1999, 42, 571-575.
11. Bolli, R. The late phase of preconditioning. Circ. Res., 2000, 87, 972-983.
12. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, 579-588.
13. Kin, H.; Zhao, Z.Q.; Sun, H. Y.; Wang, N. P.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Guyton, R.A.; Vinten-Johansen, J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc. Res., 2004, 62, 74-85.
14. Galagudza, M.; Kurapeev, D.; Minasian, S.; Valen, G.; Vaage, J. Ischemic postconditioning: brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur. J. Cardiothorac Surg., 2004, 25, 1006-1010.
15. Tsang, A.; Hausenloy, D.J.; Mocanu, M.M.; Yellon, D.M. Post-conditioning: a form of «modified reperfusion» protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res., 2004, 95, 230-232.
16. Darling, C.E.; Jiang, R.; Maynard, M.; Whittaker, P.; Vinten-Johansen, J.; Przyklenk, K. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 1618-1626.
17. Tang, X.L.; Sato, H.; Tiwari, S.; Dawn, B.; Bi, Q.; Li, Q.; Shirk, G.; Bolli, R. Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 minutes. Am. J. Physiol. Heart. Circ. Physiol., 2006, 291, 2308-2317.
18. Heusch, G. Postconditioning: old wine in a new bottle? J. Am. Coll. Cardiol., 2004, 44, 1111-1112.
19. Maeng, M.; Kristiansen, S.B.; Mortensen, U.M.; Andersen, H.R. Myocardial cooling for reperfusion injury protection achieved by organ specific hypothermic autologous perfusion. Scand. Cardiovasc. J., 2003, 37, 297-303.
20. Okamoto, F.; Allen, B.S.; Buckberg, G.D.; Schwaiger, M.; Leaf, J.; Bugyi, H.; Chen, A.; Yeatman, L.; Maloney, J.V. Regional blood cardioplegic reperfusion during total vented bypass without thoracotomy: a new concept. J. Thorac. Cardiovasc. Surg., 1986, 92, 553-563.
21. Pisarenko, O.I.; Studneva, I.M.; Lakomkin, V.L.; Timoshin, A.A.; Kapelko, V.I. Human recombinant extracellular-superoxide dismutase type C improves cardioplegic protection against ischemia/reperfusion injury in isolated rat heart. J. Cardiovasc. Pharmacol., 1994, 24, 655-663.
22. Sato, H.; Jordan, J.E.; Zhao, Z.Q.; Sarvotham, S.S.; Vinten-Johansen, J. Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann. Thorac. Surg., 1997, 64, 1099-1107.
23. Vinten-Johansen, J.; Zhao, Z.Q.; Zatta, A.J.; Kin, H.; Halkos, M.E.; Kerendi, F. Postconditioning-a new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res. Cardiol., 2005, 100, 295-310.
24. Tsai, B.M.; Wang, M.; March, K.L.; Turrentine, M.W.; Brown, J.W.; Meldrum, D.R. Preconditioning: evolution of basic mechanisms to potential therapeutic strategies. Shock, 2004, 21, 195-209.
25. Zaugg, M.; Schaub, M.C. Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning. J. Muscle Res. Cell. Motil., 2003, 24, 219-249.
26. Yellon, D.M.; Downey, J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev., 2003, 83, 1113-1151.
27. Hausenloy, D.J.; Yellon, D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc. Res., 2006, 70, 240-253.
28. Yao, Z.; Gross G.J. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am. J. Physiol., 1994, 267, 1888-1894.
29. Li, G.C.; Vasquez, J.A.; Gallagher, K.P.; Lucchesi, B.R. Myocardial protection with preconditioning. Circulation, 1990, 82, 609-619.
30. Liu, Y.; Downey, J.M. Ischemic preconditioning protects against infarction in rat heart. Am. J. Physiol., 1992, 263, 1107-1112.
31. Gho, B.C.; Schoemaker, R.G.; van den Doel, M.A.; Duncker, D.J.; Verdouw, P.D. Myocardial protection by brief ischemia in noncardiac tissue. Circulation, 1996, 94, 2193-2200.
32. Birnbaum, Y.; Hale, S.L.; Kloner, R.A. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation, 1997, 96, 1641-1646.
33. Przyklenk, K.; Darling, C.E.; Dickson, E.W.; Whittaker, P. Cardioprotection «outside the box» - the evolving paradigm of remote preconditioning. Basic Res. Cardiol., 2003, 98, 149-157.
34. Przyklenk, K.; Bauer, B.; Ovize, M.; Kloner, R.A.; Whittaker, P. Regional ischemic «preconditioning» protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation, 1993, 87, 893-899.
35. Dickson, E.W.; Porcaro, W.A.; Fenton, R.A.; Heard, S.O.; Reindhardt, C.P.; Renzi, F.P.; Przyklenk, K. «Proconditioning at a distance» in the isolated rabbit heart. Acad. Emerg. Med., 2000, 7, 311-317.
36. Dickson, E.W.; Lorbar, M.; Porcaro, W.A.; Fenton, R.A.; Reinhardt, C.P.; Gysembergh, A.; Przyklenk, K. Rabbit heart can be «preconditioned» via transfer of coronary effluent. Am. J. Physiol., 1999, 277, 2451-2457.
37. Tang, Z.L; Dai, W.; Li, Y.J.; Deng, H.W. Involvement of capsaicin-sensitive sensory nerves in early and delayed cardioprotection induced by a brief ischaemia of the small intestine. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 359, 243-247.
38. Weinbrenner, C.; Nelles, M.; Herzog, N.; Sarvary, L.; Strasser, R.H. Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway. Cardiovasc. Res., 2002, 55, 590-601.
39. Schoemaker, R.G.; van Heijningen, C.L. Bradykinin mediates cardiac preconditioning at a distance. Am. J. Physiol. Heart Circ. Physiol., 2000, 278, 1571-1576.
40. Weinbrenner, C.; Schulze, F.; Sarvary, L.; Strasser, R.H. Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart. Cardiovasc. Res., 2004, 61, 591-599.
41. Liem, D.A.; Verdouw, P.D.; Ploeg, H.; Kazim, S.; Duncker, D.J. Sites of action of adenosine in interorgan preconditioning of the heart. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, 29-37.
42. Singh, D.; Chopra, K. Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium. Methods Find. Exp. Clin. Pharmacol., 2004, 26, 117-122.
43. Wang, Y.P.; Maeta, H.; Mizoguchi, K.; Suzuki, T.; Yamashita, Y.; Oe, M. Intestinal ischemia preconditions myocardium: role of protein kinase C and mitochondrial K(ATP) channel. Cardiovasc. Res., 2002, 55, 576-582.
44. Parratt, J.R. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol. Sci., 1994, 15, 19-25.
45. Fryer, R.M.; Auchampach, J.A.; Gross, G.J. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc. Res., 2002, 55, 520-525.
46. Gross, E.R.; Gross, G.J. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res., 2006, 70, 212-221.
47. Bilinska, M.; Maczewski, M.; Beresewicz, A. Donors of nitric oxide mimic effects of ischaemic preconditioning on reperfusion induced arrhythmias in isolated rat heart. Mol. Cell Biochem., 1996, 161, 265-71.
48. Lochner, A.; Marais, E.; Genade, S.; Moolman J.A. Nitric oxide: a trigger for classic preconditioning? Am. J. Physiol., 2000, 279, 2752-2765.
49. Horimoto, H.; Gaudette, G.R.; Saltman, A.E.; Krukenkamp, I.B. The role of nitric oxide, K(+)(ATP) channels, and cGMP in the preconditioning response of the rabbit. J. Surg. Res., 2000, 92, 56-63.
50. Nakano, A.; Liu, G.S.; Heusch, G.; Downey, J.M.; Cohen, M.V. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J. Mol. Cell Cardiol., 2000, 32, 1159-1167.
51. Qin, Q.; Yang, X.M.; Cui, L.; Critz, S.D.; Cohen, M.V.; Browner, N.C.; Lincoln, T.M.; Downey, J.M. Exogenous NO triggers pre-conditioning via a cGMP- and mitoKATP-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, 712-718.
52. Cole, W.C.; McPherson, C.D.; Sontag, D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ. Res., 1991, 69, 571-581.
53. Yao, Z.; Gross, G.J. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation, 1994, 89, 1769-1775.
54. Garlid, K.D.; Paucek, P.; Yarov-Yarovoy, V.; Murray, H.N.; Darbenzio, R.B.; D'Alonzo, A.J.; Lodge, N.J.; Smith, M.A.; Grover, G.J. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res., 1997, 81, 1072-1082.
55. Ohnuma, Y.; Miura, T.; Miki, T.; Tanno, M.; Kuno, A.; Tsuchida, A.; Shimamoto, K. Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, 440-447.
56. Shojima, T.; Hayashida, N.; Nishi, A.; Takagi, K.; Hori, H.; Yoshikawa, K.; Aoyagi, S. Effects of nicorandil preconditioning on membrane dystrophin. Eur. J. Cardiothorac. Surg., 2006, 30, 472-479.
57. Das, S.; Maulik, N.; Das, D.K.; Kadowitz, P.J.; Bivalacqua, T.J. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′- monophosphate-specific phosphodiesterase 5. Drugs Exp. Clin. Res., 2002, 28; 213-219.
58. Kukreja, R.C.; Ockaili, R.; Salloum, F.; Yin, C.; Hawkins, J.; Das, A.; Xi, L. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J. Mol. Cell. Cardiol., 2004, 36, 165-173.
59. Reffelmann, T.; Kloner, R.A. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr. Pharm. Des., 2006, 12, 3485-3494.
60. Kato, R.; Foex, P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can. J. Anaesth., 2002, 49, 777-791.
61. Toller, W.G.; Kersten, J.R.; Gross, E.R.; Pagel, P.S.; Warltier, D.C. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. Anesthesiology, 2000, 92, 1400-1407.
62. Cason, B.A.; Gamperl, A.K.; Slocum, R.E.; Hickey, R.F. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology, 1997, 87, 1182-1190.
63. Toller, W.G.; Kersten, J.R.; Pagel, P.S.; Hettrick, D.A.; Warltier, D.C. Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs. Anesthesiology, 1999, 91, 1437-1446.
64. Cope, D.K.; Impastato, W.K.; Cohen, M.V.; Downey, J.M. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology, 1997, 86, 699-709.
65. Ross, S.; Foex, P. Protective effects of anaesthetics in reversible and irreversible ischaemia-reperfusion injury. Br. J. Anaesth., 1999, 82, 622-632.
66. Galagudza, M.; Vaage, J.; Valen, G. Isoflurane and other commonly used anaesthetics do not protect the isolated buffer perfused mouse heart from ischemia-reperfusion injury. Clin. Exp. Pharmacol. Physiol., 2006, 33, 315-319.
67. Tramontano, A.F.; Muniyappa, R.; Black, A.D.; Blendea, M.C.; Cohen, I.; Deng, L.; Sowers, J.R.; Cutaia, M.V.; El-Sherif, N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun., 2003, 308, 990-994.
68. Cai, Z.; Manalo, D.J.; Wei, G.; Rodriguez, E.R.; Fox-Talbot, K.; Lu, H.; Zweier, J.L.; Semenza, G.L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation, 2003, 108, 79-85.
69. Calvillo, L.; Latini, R.; Kajstura, J.; Leri, A.; Anversa, P.; Ghezzi, P.; Salio, M.; Cerami, A.; Brines, M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. USA, 2003, 100, 4802-4806.
70. Joyeux-Faure, M.; Ramond, A.; Beguin, P.C.; Belaidi, E.; Godin-Ribuot, D.; Ribuot, C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam. Clin. Pharmacol., 2006, 20, 51-56.
71. 2S) protects against regional myocardial ischemia-reperfusion injury. Evidence for a role of K ATP channels. Basic Res. Cardiol., 2006, 101, 53-60.
72. Tsuchida, A.; Thompson, R.; Olsson, R.A.; Downey, J.M. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. J. Mol. Cell Cardiol., 1994, 26, 303-311.
73. Dana, A.; Baxter, G.F.; Walker, J.M.; Yellon, D.M. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J. Am. Coll. Cardiol., 1998, 31, 1142-1149.
74. Tsuchida, A.; Liu, G.S.; Mullane, K.; Downey, J.M. Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovasc. Res., 1993, 27, 116-120.
75. Miki, T.; Miura, T.; Ura, N.; Ogawa, T.; Suzuki, K.; Shimamoto, K.; Iimura, O. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J. Am. Coll. Cardiol., 1996, 28, 1616-1622.
76. Ebrahim, Z.; Baxter, G.F.; Yellon, D.M. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism. Cardiovasc. Drugs Ther., 2004, 18, 127-134.
77. Downey, J.M.; Cohen, M.V. Reducing infarct size in the setting of acute myocardial infarction. Prog. Cardiovasc. Dis., 2006, 48, 363-371.
78. Tahepold, P.; Valen, G.; Starkopf, J.; Kairane, C.; Zilmer, M.; Wage, J. Pretreating rats with hyperoxia attenuates ischemia-reperfusion injury of the heart. Life Sci., 2001, 68, 1629-1640.
79. Tahepold, P.; Wage, J.; Starkopf, J.; Valen, G. Hyperoxia elicits myocardial protection through a nuclear factor kappaB-dependent mechanism in the rat heart. J. Thorac. Cardiovasc. Surg., 2003, 125, 650-660.
80. Song, Q.J.; Li, Y.J.; Deng, H.W. Early and delayed cardioprotection by heat stress is mediated by calcitonin gene-related peptide. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 359, 477-483.
81. Yonehara, N.; Saito, K.; Oh-ishi, S.; Katori, M.; Inoki, R. Contribution of bradykinin to heat-induced substance P release in the hind instep of rats. Life Sci., 1995, 56, 1679-1688.
82. Nakagawa, C.; Asayama, J.; Katamura, M.; Matoba, S.; Keira, N.; Kawahara, A.; Tsuruyama, K.; Tanaka, T.; Kobara, M.; Akashi, K.; Ohta, B.; Tatsumi, T.; Nakagawa, M. Myocardial stretch induced by increased left ventricular diastolic pressure preconditions isolated perfused hearts of normotensive and spontaneously hypertensive rats. Basic Res. Cardiol., 1997, 92, 410-416.
83. Huang, C.H.; Wang, J.S.; Chiang, S.C.; Wang, Y.Y.; Lai, S.T.; Weng, Z.C. Brief pressure overload of the left ventricle preconditions rabbit myocardium against infarction. Ann. Thorac. Surg., 2004, 78, 628-633.
84. Falck, G.; Schjott, J.; Jynge, P. Hyperosmotic pretreatment reduces infarct size in the rat heart. Physiol. Res., 1999, 48, 331-340.
85. Kolpakova, M.E.; Vlasov, T.D.; Petrishchev, N.N.; Vislobokov, A.I. Effect of the He-Ne laser irradiation on resistance of the isolated heart to the ischemic and reperfusion injury. Ross. Fiziol. Zh. Im. I. M. Sechenova, 2003, 89, 1496-1502.
86. Petrishchev, N.N.; Vlasov, T.D.; Galagudza, M.M.; Makov, Y.N. Effect of low-frequency low-intensity ultrasound on contractile function of isolated heart. Bull. Exp. Biol. Med., 2002, 133, 327-329.
87. Petrishchev, N.N.; Vlasov, T.D.; Galagudza, M.M.; Makov, Y.N.; Minasyan, C.M. Frequency-dependent effects of low-intensity ultrasound on activity of isolated heart. Bull. Exp. Biol. Med., 2003, 136, 239-241.
88. Vlasov, T.D.; Makov, Y.N.; Galagudza, M.M. Non-ischemic myocardial preconditioning with therapeutic ultrasound. Chin. J. Pathophysiol., 2006, 22, 38-39 (Abstract).
89. Hadour, G.; Ferrera, R.; Sebbag, L.; Forrat, R.; Delaye, J.; de Lorgeril, M. Improved myocardial tolerance to ischaemia in the diabetic rabbit. J. Mol. Cell Cardiol., 1998, 30, 1869-1875.
90. Liu, Y.; Thornton, J.D.; Cohen, M.V.; Downey, J.M.; Schaffer, S.W. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation, 1993, 88, 1273-1278.
91. Feuvray, D.; Lopaschuk, G.D. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc. Res., 1997, 34, 113-120.
92. Chen, H.; Shen, W.L.; Wang, X.H.; Chen, HZ; Gu, J.Z.; Fu, J.; Ni, Y.F.; Gao, P.J.; Zhu, D.L.; Higashino, H. Paradoxically enhanced heart tolerance to ischaemia in type 1 diabetes and role of increased osmolarity. Clin. Exp. Pharmacol. Physiol., 2006, 33, 910-916.
93. Pijl, A.J.; Hendriks, M.G.; Kam, K.L.; Pfaffendorf, M.; van Zwieten, P.A. Antiischemic effects of nifedipine in isolated working heart preparations of healthy, diabetic, and hypertensive rats. J. Cardiovasc. Pharmacol., 1994, 23, 379-386.
94. Forrat, R.; Sebbag, L.; Wiernsperger, N.; Guidollet, J.; Renaud, S.; de Lorgeril, M. Acute myocardial infarction in dogs with experimental diabetes. Cardiovasc. Res. 1993, 27, 1908-1912.
95. Ravingerova, T.; Stetka, R.; Pancza, D.; Ulicna, O.; Ziegelhoffer, A.; Styk, J. Susceptibility to ischemia-induced arrhythmias and the effect of preconditioning in the diabetic rat heart. Physiol. Res., 2000, 49, 607-616.
96. Smith, J.M.; Wahler, G.M. ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats. Mol. Cell Biochem., 1996, 158, 43-51.
97. Ramasamy, R.; Schaefer, S. Inhibition of Na+-H+ exchanger protects diabetic and non-diabetic hearts from ischemic injury: insight into altered susceptibility of diabetic hearts to ischemic injury. J. Mol. Cell Cardiol., 1999, 31, 785-797.
98. Galagudza, M.M.; Nekrasova, M.K.; Syrenskii A.V.; Nifontov, E.M. Resistance of the myocardium to ischemia and efficacy of myocardial preconditioning in experimental diabetes mellitus. Ross. Fiziol. Zh. Im. I. M. Sechenova, 2006, 92, 284-291.
99. Murcia, A.M.; Rennekens, C.H.; Lamas, G.A.; Jimenez-Navarro, M.; Rouleau, J.L.; Flaker, G.C.; Goldman, S.; Skali, H.; Braunwald, E.; Pfeffer M.A. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch. Intern. Med., 2004, 164, 2273-2279.
100. Zuanetti, G.; Latini, R.; Maggioni, A.P.; Santoro, L.; Franzosi, M.G. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J. Am. Coll. Cardiol., 1993, 22, 1788-1794.
101. del Valle, H.F.; Lascano, E.C.; Negroni, J.A.; Crottogini, A.J. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol. Cell. Biochem., 2003, 249, 21-30.
102. Nieszner, E.; Posa, I.; Kocsis, E.; Pogatsa, G.; Preda, I.; Koltai, M.Z. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic pre-conditioning in rabbits. Exp. Clin. Endocrinol. Diabetes, 2002, 110, 212-218.
103. Tsang, A.; Hausenloy, D.J.; Mocanu, M.M.; Carr, R.D.; Yellon, D.M. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes, 2005, 54, 2360-2364.
104. Ishihara, M.; Sato, H.; Kawagoe, T.; Shimatani, Y.; Kurisu, S.; Nishioka, K.; Kouno, Y.; Umemura, T.; Nakamura, S. Impact of diabetes mellitus on long term survival after acute myocardial infarction in patients with single vessel disease. Heart, 2001, 86, 133-138.
105. Hassouna, M.; Loubani, B.; Matata, A.; Fowler, N.; Standen, M.; Galinanes, M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc. Res., 2006, 69, 450-458.
106. Mocanu, M.M.; Maddock, H.L.; Baxter, G.F.; Lawrence, C.L.; Standen, N.B.; Yellon, D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation, 2001, 103, 3111-3116.
107. Pantos, C.; Malliopoulou, V.; Varonos, D.D.; Cokkinos, D.V. Thyroid hormone and phenotypes of cardioprotection. Basic Res. Cardiol., 2004, 99, 101-120.
108. Pantos, C.I.; Malliopoulou, V.A.; Mourouzis, I.S.; Karamanoli, E.P.; Paizis, I.A.; Steimberg, N.; Varonos, D.D.; Cokkinos, D.V. Long-term thyroxine administration protect the heart in a pattern similar to ischemic preconditioning. Thyroid, 2002, 12, 325-329.
109. Pantos, C.; Malliopoulou,V.; Mourouzis, I.; Karamanoli, E.; Moraitis, P.; Tzeis, S.; Paizis, I.; Cokkinos, A.D.; Carageorgiou, H.; Varonos, D.D.; Cokkinos, D.V. Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur. J. Pharmacol., 2003, 478, 53-60.
110. Pantos, C.; Malliopoulou, V.; Mourouzis, I.; Thempeyioti, A.; Paizis, I.; Dimopoulos, A.; Saranteas, T.; Xinaris, C.; Cokkinos, D.V. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm. Metab. Res., 2006, 38, 308-313.
111. Pantos, C.; Malliopoulou, V.; Paizis, I.; Panagiotis, M.; Mourouzis, I.; Tzeis, S.; Karamanoli, E.; Cokkinos, D.; Carageorgiou, H.; Varonos, D.; Cokkinos, D. Thyroid hormone and cardioprotection: study of p3 8 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol. Cell. Biochem., 2003, 242, 73-80.
112. Pantos, C.; Malliopoulou, V.; Mourouzis, I.; Sfakianoudis, K.; Tzeis, S.; Doumba, P.; Xinaris, C.; Cokkinos, A.D.; Carageorgiou, H.; Varonos, D.D.; Cokkinos, D.V. Propylthiouracil-induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischaemia-reperfusion. J. Endocrinol., 2003, 178, 427-435.
113. Zhang, L.; Parratt, J.R.; Beastall, G.H.; Pyne, N.J.; Furman, B.L. Streptozotocin diabetes protects against arrhythmias in rat isolated hearts: role of hypothyroidism. Eur. J. Pharmacol., 2002, 435, 269-276.
114. Radak, Z.; Sasvari, M.; Nyakas, C.; Pucsok, J.; Nakamoto, H.; Goto, S. Exercise preconditioning against hydrogen peroxide-induced oxidative damage in proteins of rat myocardium. Arch. Biochem. Biophys., 2000, 376, 248-251.
115. Venditti, P.; Masullo, P.; Di Meo, S.; Agnisola, C. Effects of prolonged aerobic exercise on myocardial responses to ischaemia-reperfusion in the rat. Exp. Physiol., 2001, 86, 341-348.
116. Eisen, A.; Fisman, E.Z.; Rubenfire, M.; Freimark, D.; McKechnie, R.; Tenenbaum, A.; Motro, M.; Adler, Y. Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis, 2004, 172, 201-210.
117. Petrishchev, N.N.; Vlasov, T.D.; Sipovsky, V.G.; Kurapeev, D.I.; Galagudza, M.M. Does nitric oxide generation contribute to the mechanism of remote ischemic preconditioning? Pathophysiology, 2001, 7, 271-274.
118. Saini, H.K.; Machackova, J.; Dhalla, N. S. Role of reactive oxygen species in ischemic preconditioning of subcellular organelles in the heart. Antioxid. Redox. Signal., 2004, 6, 393-404.
119. 2+ as a mediator of ischemic preconditioning. Circ. Res., 1997, 80, 790-799.
120. Wallbridge, D.R.; Schulz, R.; Braun, C.; Post, H.; Heusch, G. No attenuation of ischemic preconditioning by the calcium antagonist nisoldipine. J. Mol. Cell. Cardiol., 1996, 28, 1801-1810.
121. Armstrong, S.C. Protein kinase activation and myocardial ischemia/ reperfusion injury. Cardiovasc. Res., 2004, 61, 427-436.
122. Garlid, K.D.; Paucck, P.; Yarov-Yarovoy, V.; Murray, H.N.; Darbenzio, R.B.; D'Alonzo, A.J.; Lodge, N.J.; Smith, M.A.; Grover, G.J. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res., 1997, 81, 1072-1082.
123. Liu, Y.; Sato, T.; O'Rourke, B.; Marban, E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation, 1998, 97, 2463-2469.
124. 2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ. Res., 2001, 89, 891-898.
125. Krenz, M.; Oldenburg, O.; Wimpee, H.; Cohen, M.V.; Garlid, K.D.; Critz, S.D.; Downey, J.M.; Benoit; J.N. Opening of ATP-sensitive potassium channels causes generation of free radicals in vascular smooth muscle cells. Basic Res. Cardiol., 2002, 97, 365-373.
126. Korge, P.; Honda, H.M.; Weiss, J.N. K+-dependent regulation of matrix volume improves mitochondrial function under conditions mimicking ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 66-77.
127. Hanley, P.J.; Daut, J. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J. Mol. Cell. Cardiol., 2005, 39, 17-50.
128. Gross, G.J.; Auchampach, J.A. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ. Res., 1992, 70, 223-233.
129. Auchampach, J.A.; Grover, G.J.; Gross, G.J. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc. Res., 1992, 26, 1054-1062.
130. Hanley, P.J; Drose, S.; Brandt, U.; Lareau, R.A.; Banerjee, A.L.; Srivastava, D.K.; Banaszak, L.J.; Barycki, J.J.; Van Veldhoven, P.P.; Daut, J. 5-Hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for beta-oxidation of fatty acids. J. Physiol., 2005, 562, 307-318.
131. Minners, J.; van den Bos, E.J.; Yellon, D.M.; Schwalb, H.; Opie, L.H.; Sack, M.N. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc. Res., 2000, 47, 68-73.
132. Hearse, D.J. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc. Res., 1995, 30, 1-17.
133. Suzuki, M.; Sasaki, N.; Miki, T.; Sakamoto, N.; Ohmoto-Sekine, Y.; Tamagawa, M.; Seine, S.; Marban, E.; Nakaya, H. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J. Clin. Invest., 2002, 109, 509-516.
134. Vanden Hoek, T.L.; Li, C.; Shao, Z.; Schumacker, P.T.; Becker, L.B. Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion. J. Mol. Cell Cardiol., 1997, 29, 2571-2583.
135. Ambrosio, G.; Zweier, J.L.; Duilio, C.; Kuppusamy, P.; Santoro, G.; Elia, P.P.; Tritto, I.; Cirillo, P.; Condorelli, M.; Chiariello, M. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J. Biol. Chem., 1993, 268, 18532-18541.
136. Novalija, E.; Kevin, L.G.; Camara, A.K.; Bosnjak, Z.J.; Kampine, J.P.; Stowe, D.F. Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade. Anesthesiology, 2003, 99, 421-428.
137. Halestrap, A.P.; Clarke, S.J.; Javadov, S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res., 2004, 61, 372-385.
138. Murphy, E.; Steenbergen, C. Preconditioning: the mitochondrial connection. Annu. Rev. Physiol., 2007, 69, 51-67.
139. Tsang, A.; Hausenloy, D.J.; Yellon, D.M. Myocardial postconditioning: reperfusion injury revisited. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, 2-7.
140. Kin, H.; Zatta, A.J.; Lofye, M.T.; Amerson, M.; Halkos, F.; Kerendi, Z.; Zhao, R.; Guyton, R.A.; Headrick, J.; Vinten-Johansen, J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosinc. Cardiovasc. Res., 2005, 67, 124-133.
141. Yang, X.M.; Philipp, S.; Downey, J.M.; Cohen, M.V. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res, Cardiol., 2005. 100, 57-63.
142. Yellon, D.M.; Downey, J.M. Current research views on myocardial reperfusion and reperfusion injury. Cardioscience, 1990, 1, 89-98.
143. Hausenloy, D.J.; Yellen, D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 2004, 61, 448-460.
144. Jonassen, A.K.; Sack, M.N.; Mjos, O.D.; Yellon, D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ.- Res., 2001, 89, 1191-1198.
145. Bell, R.M.; Yellon, D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of P13K, Akt and eNOS. J. Mol. Cell Cardiol., 2003, 35, 185-193.
146. Baxter, G.F.; Mocanu, M.M.; Brar, B.K.; Latchman, D.S.; Yellon, D.M. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J. Cardiovasc. Pharmacol., 2001, 38, 930-939.
147. Bell, R.M.; Yellon, D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol., 2003, 41, 508-515.
148. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109, 962-965.
149. Zatta, A.J.; Kin, H.; Lee, G.; Wang, N.; Jiang, R.; Lust, R.; Reeves, J.G.; Mykytenko, J.; Guyton, R.A.; Zhao, Z.Q.; Vinten-Johansen, J. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc. Res., 2006, 70, 315-324.
150. Argaud, L.; Gateau-Roesch, O.; Raisky, O. Postconditioning inhibits mitochondrial permeability transition. Circulation, 2005, 111, 194-197.
151. Bopassa, J.C.; Ferrera, R.; Gateau-Roesch, O.; Couture-Lepetit, E.; Ovize, M. PI3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc. Res., 2006, 69, 178-185.
152. Hausenloy, D.J.; Maddock, H.L.; Baxter, G.F.; Yellon, D.M. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc. Res., 2002, 55, 534-543.
153. Kerendi, F.; Kin, H.; Halkos, M.E.; Jian, R.; Zatta, A.J.; Zhao, Z.Q.; Guyton, R.A.; Vinten-Johansen, J. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res. Cardiol., 2005, 100, 404-412.
154. Jenkins, D.P.; Steare, S.E.; Yellon, D.M. Preconditioning the human myocardium: recent advances and aspirations for the development of a new
155. Baxter, G.F.; Yellon, D.M. Ischaemic preconditioning of myocardium: a new paradigm for clinical cardioprotection? Br. J. Clin. Pharmacol., 1994, 38, 381-387.
156. Yellon, D.M.; Alkhulaifi, A.M.; Pugsley, W.B. Preconditioning the human myocardium. Lancet, 1993, 342, 276-277.
157. Jenkins, D.P.; Pugsley, W.B.; Alkhulaifi, A.M.; Kemp, M.; Hooper, J.; Yellon, D.M. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart, 1997, 77, 314-318.
158. Cremer, J.; Steinhoff, G.; Karck, M.; Almsell, T.; Brandt, M.; Teebken, O. E.; Hollander, D.; Haverich, A. Ischemic preconditioning prior to myocardial protection with cold blood cardioplegia in coronary surgery. Eur. J. Cardiothorac Surg., 1997, 12, 753-758.
159. Perrault, L.P.; Menascbe, P.; Bel, A.; Chaumaray, T.; Peynct, J.; Mondry, A.; Olivero, P.; Emanoil-Ravier, R.; Moalic, J.M. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac. Cardiovasc. Surg., 1996, 112, 1378-1386.
160. Wu, Z.K.; Tarkka, M.R.; Eloranta, J.; Pehkonen, E.; Laurikka, J.; Kaukinen, L.; Honkonen, E.L.; Vuolle, M. Kaukinen, S. Effect of ischaemic preconditioning, cardiopulmonary bypass and myocardial ischaemic/reperfusion on free radical generation in CABG patients. Cardiovasc. Surg., 2001, 9, 362-368.
161. Wu, Z.K.; Pehkonen, E.; Laurikka, J.; Kaukinen, L.; Honkonen, E.L.; Kaukinen, S.; Laippala, P.; Tarkka, M.R. The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 2001, 122, 972-978.
162. Wu, Z.K.; Iivainen, T.; Pehkonen, E.; Laurikka, J.; Tarkka, M.R. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation, 2002, 106, 3091-3096.
163. Wu, Z.K.; Tarkka, M.R.; Pehkonen, E.; Kaukinen, L.; Honkonen, E.L.; Kaukinen, S. Beneficial effects of ischemic preconditioning on right ventricular function after coronary artery bypass grafting. Ann. Thorac. Surg., 2000, 70, 551-557.
164. Vaage J.; Valen G. Preconditioning and cardiac surgery. Ann. Thorac. Surg., 2003, 75, 709-714.
165. Bums, P.G.; Krukenkamp, I.B.; Caldarone, C.A.; Gaudette, G.R.; Bukhari, E.A.; Levitsky, S. Does cardiopulmonary bypass alone elicit myoprotective preconditioning? Circulation, 1995, 92, 447-451.
166. Ramzy, D.; Rao, V.; Weisel, R. Clinical applicability of preconditioning and postconditioning: The cardiothoracic surgeons's view? Cardiovasc. Res., 2006, 70, 174-180.
167. Gunaydin, B.; Cakici, I.; Soncul, H.; Kalaycioglu, S.; Cevik, C.; Sancak, B.; Kanzik, I.; Karadenizli, Y. Does remote organ ischaemia trigger cardiac preconditioning during coronary artery surgery? Pharmacol. Res., 2000, 41, 493-496.
168. Cheung, M.M.; Kharbanda, R.K.; Konstantinov, I.E.; Shimizu, M.; Frndova, H.; Li, J.; Holtby, H.M.; Cox, P.N.; Smallhorn, J.F.; Van Arsdell, G.S.; Redington, A.N. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J. Am. Coll. Cardiol., 2006, 47, 2277-2282.
169. Kloner, R.A.; Shook, T.; Przyklenk, K.; Davis, V.G.; Junio, L.; Matthews, RX; Burstein, S.; Gibson, C.M.; Poole, W.K.; Cannon, C.P.; McCabe, C.H.; Braunwald, E. Previous angina alters inhospital outcome in TIMI 4 a clinical correlate to preconditioning? Circulation, 1995, 91, 37-45.
170. Kloner, R.A.; Przyklenk, K.; Shook, T.; Cannon, C.P. Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI 4 trial. J. Thromb. Thrombolysis, 1998, 6, 89-92.
171. Paraskevaidis, I.A.; Iliodromitis, E.K.; Mavrogeni, S.; Karavolias, G.K.; Theodorakis, G.N.; Georgiadis, M.; Kremastinos, D.T. Repeated exercise stress testing identifies early and late preconditioning. Int. J. Cardiol., 2005, 98, 221-226.
172. Rezkalla S.H.; Kloner, R.A. Ischemic preconditioning for the clinician. WJM, 2006, 105, 22-26.
173. Kloner, R.A.; Rezkalla, S.H. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc. Res., 2006, 70, 297-307.
174. Mentzer, R.M.; Rahko, P.S.; Molina-Viamonte, V.; Canver, C.C.; Chopra, P.S.; Love, R.B.; Cook, T.D.; Hegge, J.O.; Lasley, R.D. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am. J. Cardiol., 1997, 79, 38-43.
175. Mentzer, R.M.; Birjiniuk, V.; Khuri, S.; Lowe, J.E.; Rahko, P.S.; Weisel, R.D.; Wellons, H.A.; Barker, M.L.; Lasley, R.D. Adenosine myocardial protection preliminary results of a phase II clinical trial. Ann. Surg., 1999, 229, 643-649.
176. Wasir, H.; Bhan, A.; Choudhary, S.K.; Sharma, R.; Chauhan, S.; Venugopal, P. Pretreatment of human myocardium with adenosine. Eur J Cardiothorac. Surg., 2001, 19, 41-46.
177. Teoh, L.K.; Grant, R.; Hulf, J.A.; Pugsley, W.B.; Yellon, D.M. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc. Res., 2002, 53, 175-180.
178. Belhomme, D.; Peynet, J.; Florens, E.; Tibourtine, O.; Kitakaze, M.; Menasche, P. Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery? Ann. Thorac. Surg., 2000, 70, 590-594.
179. Leesar, M.A.; Stoddard, M.F.; Xuan, Y.T.; Tang, X.L.; Bolli, R. Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. J. Am. Coll. Cardiol., 2003, 42, 437-445.
180. Kopecky, S.L.; Aviles, R.J.; Bell, M.R.; Lobl, J.K.; Tipping, D.; Frommell, G.; Ramsey, K.; Holland, A.E.; Midei, M.; Jain, A.; Kellett, M.; Gibbons, R.J. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am. Heart J., 2003, 146, 146-152
181. Belhomme, D.; Peynet, J.; Louzy, M.; Launay, J.; Kitakaze, M.; Menasche, P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation, 1999, 100, 340-344.
182. De Hert, S.G. Cardioprotection with volatile anesthetics: clinical relevance. Curr. Opin. Anaesthesiol., 2004, 17, 57-62.
183. Garcia, C.; Julier, K.; Bestmann, L.; Zollinger, L.; Segesser, K.; Pasch, T.; Spalm, D. R.; Zaugg, M. Preconditioning with sevoflurane decreases PECAM 1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br. J. Anaesth., 2005, 94, 159-165.
184. Kawamura, T.; Kadosaki, M.; Nara, N.; Wei, J.; Endo, S. Nicorandil attenuates NF-kappaB activation, adhesion molecule expression, and cytokine production in patients with coronary artery bypass surgery. Shock, 2005, 24, 103-108.
185. Blanc, P.; Aouifi, A.; Bouvier, H.; Joseph, P.; Chiari, P.; Ovize, M.; Girard, C.; Jegaden, O.; Khder, Y.; Lehot, J.J.; Inada, K. Safety of oral nicorandil before coronary artery bypass graft surgery. Br. J. Anaesth., 2001, 87, 848-854.
186. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet, 2002, 359, 1269-1275.
187. Doorey, A.J.; Mehmel, H.C.; Schwarz, F.X.; Kohler, W. Amelioration by nitroglycerin of left ventricular ischemia induced by percutaneous transluminal coronary angioplasty: assessment by hemodynamic: variables and left ventriculography. J. Am. Coll. Cardiol., 1985, 6, 267-274.
188. Leesar, M.A.; Stoddard, M.F.; Dawn, B.; Jasti, V.G.; Masden, R.; Bolli, R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation, 2001, 103, 2935-2941.
189. Leesar, M.A.; Stoddard, M.F.; Manchikalapudi, S.; Bolli, R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J. Am. Coll. Cardiol., 1999, 34, 639-650.
190. Ghosh, S.; Standen, N.B.; Galinianes, M. Failure to precondition pathological human myocardium. J. Am. Coll. Cardiol., 2001, 37, 711-718.
191. Kyriakides, Z.S.; Psychari, S.; Iliodromitis, E.K.; Kolettis, T.M.; Sbarouni, E.; Kremastinos, D.T. Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Chest, 2002, 121, 1211-1215.
192. Ungi, I.; Ungi, T.; Ruzsa, Z.; Nagy, E.; Zimmermann, Z.; Csont, T.; Ferdinandy, P. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest, 2005, 128, 1623-1628.
193. Staat, P.; Rioufol, G.; Piot, C.; Cottin, Y.; Cung, T.T.; L'Huillier, I.; Aupetit, J.F.; Bonnefoy, E.; Finet, G.; Andre-Fouet, X.; Ovize, M. Postconditioning the human heart. Circulation, 2005, 112, 2143-2148.
194. Loukogeorgakis, S.P.; Panagiotidou, A.T.; Yellon, D.M.; John, E.; Deanfield, B.A.; MacAllister, R.J. Postconditioning protects against endothelial ischemia - reperfusion injury in the human forearm. Circulation, 2006, 113, 1015-1019.